Displaying drugs 15076 - 15100 of 15308 in total
Guanoclor
Experimental
Clofibride
Experimental
Imiglitazar
Imiglitazar has been used in trials studying the treatment of Diabetes Mellitus.
Investigational
5-(PARA-NITROPHENYL PHOSPHONATE)-PENTANOIC ACID
Experimental
Carmegliptin
Carmegliptin has been used in trials studying the treatment of Diabetes Mellitus Type 2.
Investigational
XMT-1001
XMT-1001 is a polymer-based prodrug of camptothecin (CPT), a well-characterized topoisomerase I inhibitor with potent anti-tumor activity. It is a water-soluble macromolecular conjugate of camptothecin (CPT). In this novel CPT pro-drug, CPT is conjugated with a 70 kDa biodegradable hydrophilic polyacetal, poly (1-hydroxymethylene hydroxylmethylformal). XMT-1001 has demonstrated an improved therapeutic...
Investigational
Matched Description: … XMT-1001 has demonstrated an improved therapeutic window as compared with CPT and irinotecan in human …
Nelotanserin
Nelotanserin has been used in trials studying the treatment of Lewy Body Dementia, Visual Hallucinations, Dementia With Lewy Bodies, and REM Sleep Behavior Disorder. It is a highly selective antagonist at the 5-HT2A serotonin receptor. It increases non-REM sleep, the most restorative phase of the sleep cycle, without sacrificing REM...
Investigational
Matched Description: … trials studying the treatment of Lewy Body Dementia, Visual Hallucinations, Dementia With Lewy Bodies, and …
Balanol Analog 2
Experimental
N-[3-(aminomethyl)benzyl]acetamidine
Experimental
Iodobenzene
Experimental
ES-936
Experimental
AL7182
Experimental
S-Ethyl-N-[4-(Trifluoromethyl)Phenyl]Isothiourea
Experimental
4-(2-Thienyl)-1-(4-Methylbenzyl)-1h-Imidazole
Experimental
PAS219
Experimental
Phenacetin
Phenacetin was withdrawn from the Canadian market in June 1973 due to concerns regarding nephropathy (damage to or disease of the kidney).
Withdrawn
1,3,5-trichlorobenzene
Experimental
Displaying drugs 15076 - 15100 of 15308 in total